{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1380861711802179074.json","@type":"Researcher","foaf:Person":[{"foaf:name":[{"@value":"Anne Françoise DILLIES-LEGRAIN"}],"foaf:familyName":[{"@value":"DILLIES-LEGRAIN"}],"foaf:givenName":[{"@value":"Anne Françoise"}]}],"product":[{"@id":"https://cir.nii.ac.jp/crid/1360861711802179072","@type":"Article","productIdentifier":[{"@type":"DOI","@value":"10.1016/s1470-2045(20)30755-5"},{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S1470204520307555?httpAccept=text/xml"},{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S1470204520307555?httpAccept=text/plain"}],"notation":[{"@value":"Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial"}],"relation":[{"type":"creator"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1016/s1470-2045(20)30755-5_UPIxZzVitN5t9wJ19ftJOtOs0me"}]}